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INTRODUCTION 
 Hepatocellular carcinoma (HCC) is a major health problem 
worldwide, due to its high incidence (approximately 600 000 new cases 
in 2008), and high rates of Mortality.  It results in 598 000 deaths per year 
worldwide.(1) The incidence of HCC is increasing in almost all 
geographical areas and this neoplasm currently represents the third cause 
of cancer related death.  In >90% of the cases, cirrhosis of any aetiology 
underlies HCC and the development of HCC constitutes their most 
frequent cause of death.   
 Overall, 75–80% of global HCC cases are due to hepatitis B virus 
(HBV) (50–55%) or hepatitis C virus (HCV) (25–30%). The 
identification that chronic liver disease is the relevant risk factor for this 
tumor, has made surveillance campaigns aimed at early detection of HCC 
possible and surveillance is now universally recognized to be the practical 
approach for improving treatment of HCC patients. 
 From a global perspective, the two most important risk factors for 
HCC are chronic hepatitis B and C infection.  The geographic distribution 
patterns of HCC and HBV almost coincide with each other. Recent 
studies demonstrated that the Taiwanese mass vaccination program 
against HBV has significantly reduced the carrier rate of HBsAg in 
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children and adolescents and, as anticipated, the incidence of childhood 
HCC. A substantial decrease in HCC incidence in adults may be observed 
in 3–4 decades.  
 In contrast, the incidence of HCC has risen in the past 10–20 years 
in several developed countries such as the United States, Japan, England, 
and France where HBV is not endemic. Recent review suggested that a 
cohort effect related to HCV infection may likely contribute to the 
increasing disease burden in these countries. In India, the mean incidence 
of HCC in four population-based registries is 2.77% for males and 1.38% 
for females. The prevalence of HCC in India varies from 0.2% to 1.6%.  
The characteristics of patients with HCC are influenced by the etiology 
and the status of the underlying liver disease.  The understanding of its 
natural history may influence the prognosis and choice of treatment.  
 Most of the published literatures were retrospective studies and 
moreover limited number of studies available for South Indian 
population. 
 Hence we have undertaken this prospective study to analyze the 
natural history of HCC, especially with regard to patients with cirrhosis. 
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AIMS & OBJECTIVE OF THE STUDY 
 
 To prospectively study the natural history of Hepatocellular 
Carcinoma  in patients with cirrhotic background in a tertiary care 
hospital. 
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REVIEW OF LITERATURE 
 Hepatocellular carcinoma (HCC) is the third most common cause 
of cancer death in the world resulting in 598 000 deaths per year 
worldwide. Because of its poor prognosis, this number of deaths is almost 
the same as the number of cases being diagnosed each year (626 000) (1).  
 From a global perspective, the two most important risk factors for 
HCC are chronic hepatitis B and C infection.(2)  The geographic 
distribution patterns of HCC and HBV almost coincide with each other. 
The characteristics of patients with HCC are influenced by the etiology 
and the status of the underlying liver disease.  The understanding of its 
natural history may influence the prognosis and choice of treatment of 
HCC represents more than 5% of all cancers in the world. With the 
significant increase in the number of patients who have HCC, early 
detection and treatment of this tumor are vital to improve outcomes. 
Epidemiology 
Worldwide Distribution 
 Liver cancer incidence rate varies widely from 52.1 per 100 000 in 
China to 5.1 per 100 000 in Northern Europe.  Developing countries 
contribute more than 80% of cases with China alone accounting for 55% 
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(1). More than 80% of HCC cases occur in either sub-Saharan Africa or 
in Eastern Asia. China alone accounts for more than 50% of the world’s 
cases (men, 35.2/100,000; women, 13.3/100,000).(62) North and South 
America, and Northern Europe found to have low incidence 
(<5.0/100,000) of liver cancer among most populations. United Kingdom 
(male, 2.2/100,000; female, 1.1/100,000) and Australia (male, 
3.6/100,000; female, 1.0/100,000) also noted low tumor burden.   Other 
areas, with high incidences are sub-Saharan Africa, eastern and 
southeastern Asia, and Melanesia.(16)  
 It is believed that effective HBV vaccination programmes and the 
better control of aflatoxin exposure in the high HCC incidence areas are 
contributing to the decreased HCC incidence while the increasing HCC 
incidence in some of the western countries is attributed to the increasing 
prevalence of hepatitis C virus (HCV) infection and immigration of 
people from countries with high endemicity for HBV infection. Neonatal 
vaccinations against hepatitis B virus (HBV) and shift the staple diet from 
corn to rice (limit the exposure to aflatoxin B1) lowered the incidence of 
HCC in Asian countries. 
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Race/Ethnicity 
 HCC incidence rates vary greatly among different populations 
living in the same region. In United States, HCC rates are 2 times higher 
in Asians than in African Americans, whose rates are 2 times higher than 
those in whites. The reason for this ethnic variability includes differences 
in the prevalence and acquisition time of major risk factors for liver 
disease and HCC. (17) 
Age & Sex 
 There is no evidence that advanced age per se is associated with 
greater cancer aggressiveness. Confounding factors such as shorter life 
expectancy, higher prevalence of co-morbidities and less ‘aggressive’ 
therapeutic management could explain the negative impact of age on 
prognosis. In fact, the adverse effect of age disappeared when patients 
were segregated according to the treatment received  . In almost all, males 
have higher liver cancer rates than females, with male: female ratios 
usually averaging between 2:1 and 4:1.  The reasons for higher rates of 
liver cancer in males may relate to sex-specific differences in exposure to 
risk factors. Men are more likely to be infected with HBV and HCV, 
consume alcohol, smoke cigarettes, and have increased iron stores.  
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Age 
 The global age distribution of HCC varies by region, incidence 
rate, sex, and by etiology. Male sex is an established risk factor for HCC 
in patients with chronic liver diseases(9) , whereas gender influence on 
HCC progression and prognosis remains controversial.  Androgen 
hormones have been claimed as responsible for the greater cancer risk 
and grim prognosis . Among the low-risk populations (United States, 
Canada, and United Kingdom), HCC commonly occurs in persons aged 
75 and older.  
 A similar pattern is seen among most high-risk Asian populations 
(Hong Kong and Shanghai). In contrast, male rates in high-risk African 
populations tend to peak between ages 60 and 65, whereas female rates 
peak between 65 and 70. These variable age specific patterns likely are 
related to differences in the dominant hepatitis virus in the population, the 
age at viral infection, and the existence of other risk factors.  Although 
most HCV infections acquired in adulthood, but most HBV carriers 
became infected at very young ages. 
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DIFFERENT HCC PATTERNS 
 HCCs in South Africa are mostly large sized and poorly 
differentiated with relatively healthy surrounding liver tissues. On the 
contrary, HCCs in non-African countries are relatively smaller in size and 
more differentiated with a background of cirrhotic liver. This can be the 
result of the difference in etiologies. Aflatoxin B1, a mycotoxin produced 
by Aspergillus species-- major carcinogenic factor in the South African 
population. Chronic hepatitis and the resultant cirrhosis are important risk 
factors in non-Africans. The distinct fibrolamellar type of HCC almost 
exclusively found in young Caucasian patients may be due to ethnic 
factor. 
HCC in Asia 
 In China and Taiwan, almost one-fifth of the populations are 
carriers of HBV, and the majority of persons with HCC are HBsAg-
positive(60). In contrast to the rest of Asia, cases of HCC in Japan are 
mainly related to HCV infection, and its incidence is rising but on a larger 
scale. The reasons underlying this difference are likely related to the wide 
transmission of HCV to young people in Japan from contaminated blood 
and needles after the Second World War. In Japanese patients with 
  9
chronic viral hepatitis, the progression to HCC occurs at an accelerated 
rate in HCV infection compared with HBV infection. (58,59) 
HCC in India 
 Most Asian countries are in intermediate or high incidence zones of 
HCC. In India, the mean incidence of HCC in four population-based 
registries is 2.77% for males and 1.38% for females. HCC accounted for 
1.9% of the 24,975 cases of cancers recorded at 6 registries put together; 
the proportion ranging from 1.1% (94/8763) in Delhi to 5.3% (10/187) in 
Barshi rural registry.  The prevalence of HCC in India varies from 0.2% 
to 1.6%.(61) In India HBV is the main etiological factor associated with 
HCC.  However, in India, most of the patients in clinical practice present 
at an advanced stage ruling out curative treatment in most cases.  
A prospective study by Paul et al revealed the estimated incidence of 
HCC among cirrhotic patients was 1.6% per year.(66) 
Risk Factors and Pathogenesis of HCC 
Hepatocellular carcinoma is multi factorial in etiology and complex 
in pathogenesis. The main established risk factors for HCC development 
are chronic viral hepatitis B and C infection and aflatoxin B1.(76). Liver 
cirrhosis per se may also lead to HCC development. Hepatitis C infection 
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probably causes HCC  through the pathway of cirrhosis. Alcoholic liver 
disease, autoimmune liver diseases, primary hemochromatosis and 
Wilson’s disease are also associated with the development of HCC. 
Overall, hepatitis B and C infections are causally associated with over 
80% of HCC in the world. 
 Worldwide, 400 million people infected with chronic hepatitis B, 
75% of whom are Asians. The natural history of chronic hepatitis B 
infection in Asian and African countries is different from that in the 
western world. In Asia and Africa, the majority of the people acquire the 
infection during the perinatal period or during very early childhood. 
There is characteristically prolonged immune tolerance phase in the first 
few decades of life.  The lifetime risk of HCC in infected men is 
estimated to be 10% to 25% while the risk in women is somewhat lower  
 Case-control studies - chronic HBV carriers have more than 100-
fold increased risk of HCC compared with non- infected individuals.  
Furthermore, the risk of HCC development is related to the disease status 
of chronic hepatitis B infection. For example, the estimated annual risk of 
HCC in chronic carriers is 0.26% to 0.6%. The risk increases to 1% in 
patients with active hepatitis . It further increases to 2% to 3% in cirrhotic 
patients. Studies in Taiwan showed that genotype C chronic hepatitis B 
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infection has a more aggressive progression than genotype B in HBeAg 
positive patients.  Core promoter mutations (T1762. A1764) are also 
found to be related to a more progressive disease . In the majority of HCC 
cases (70% to 90%), there is underlying liver cirrhosis. However, HBV, 
being an oncogenic virus, can cause HCC in the absence of cirrhosis 
through the pathway of integration into the human genome. 
Major Risk Factors (67) 
¾ Chronic hepatitis B virus infection  
¾ Chronic hepatitis C virus infection  
¾ Cirrhosis  
¾ Dietary exposure to aflatoxin B1  
Minor Risk Factors  
¾ Oral contraceptive steroids  
¾ Cigarette smoking  
¾ Dietary iron overload in persons of black African ancestry  
¾  Hereditary hemochromatosis  
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¾  Wilson disease  
¾  α1-Antitrypsin deficiency  
¾ Type 1 hereditary tyrosinemia 
¾ Type 1 and type 2 glycogen storage disease  
¾  Membranous obstruction of the inferior vena cava 
Hepatitis B Virus 
 In the meta-analysis of 32 case control studies by McMahon et 
al.,(45) concomitant infection with HBV and HCV was associated with 
an odds ratio of 165 (95% CI, 81 to 374) as compared with an odds ratio 
of 17 with HCV positivity alone and an odds ratio of 23 with HBV 
positivity alone, thus, suggesting a synergism between the 2 infections. 
Carcinogenesis of HCC is a multi-step process involving a number of 
different genetic alterations that ultimately lead to malignant 
transformation of the hepatocyte. It is postulated that HBV infection 
causes HCC via direct and indirect pathways.  
 Continuous hepatocyte injury and regeneration in cirrhosis of the 
liver leads to increased liver cell turn over and hence accumulation of 
critical mutations in the host genome  resulting  in genetic alterations, 
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such as chromosomal rearrangements as well as activation of cellular 
oncogenes or inactivation of tumor suppressor genes. However a higher 
rate of chromosomal abnormalities is found in HBV-related HCC than 
those linked to other risk factors (45). The HBsAg positivity in Indian 
HCC patients varies from 36% to 74%. 10, 11. 
 India in an intermediate endemic zone for HBV has low incidence 
of HCC unlike other Asian countries. The relative risk of developing 
HCC in Indian patients with chronic HbsAg infection estimated to be 7.8 
- studies. 
 HBV belongs to the group of oncogenic viruses known as hepadna 
virus. It is able to integrate its DNA into the genome of the infected cell. 
Integrated HBV sequences have been observed in established hepatoma 
cell lines and in about 80% of human HBV related HCCs .  It is 
postulated, that the HBV DNA integration may confer a selective growth 
advantage on target cells and leads to the onset of tumor progression. The 
integration sites are frequently detected in cellular genes involving cell 
signaling or growth control. Host chromosomal instability is also 
enhanced by HBV DNA integration. Large inverted duplications, 
deletions, amplification, chromosomal translocation have all been 
observed to be associated with HBV integration(46,47). Regulatory 
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proteins HBx and the PreS2 activators can exert a tumor promoter-like 
function, resulting in positive selection of cells producing a functional 
regulatory protein. Hepatitis B vaccination  - recognized as the most 
effective measure to prevent HBV infection and HBV-associated 
complications, including HCC. The first evidence came from Taiwanese 
study - HCC is preventable via effective vaccination. The average 
incidence of HCC declined from 0.7 (1982 to 1986) to 0.36 (1990 to 
1994) per 100,000 children(36,41,47). And there was a similar decline in 
the mortality associated with HCC. HBV-related HCC is predominant in 
male, with a male to female ratio of 5–7:1. This is attributed to the 
elevated androgen level and the enhanced androgen receptor (AR)-
mediated activity in the host. HBx is a noncellular positive coregulator 
for androgen receptors makes males vulnerable to HBV infection & 
subsequent development of cancer. HBx protein may play a significant 
role in inducing the expression of angiopoietin-2; contribute to 
pathological angiogenesis and Hepatocellular carcinoma progression. 
Hepatitis C Virus 
 Several lines of evidence indicate a strong causal association 
between HCV and HCC.  Markers of HCV infection are found in a 
variable proportion of HCC cases in Europe with an increasing gradient 
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from North to South (44); for example,44% to 66% in Italy,27% to 58% 
in France, 60% to75% in Spain,and in 80% to 90% of HCC cases in 
Japan.  Moreover, the age-standardized death rates owing to HCC(49) in 
several European countries are significantly correlated with the 
seroprevalence of HCV in the general population. 
 Of 1,429 patients assumed to have been tested, 384 (27%) were 
positive for HCV.11-15. Higher proportion of patients with HCC might 
have had HCV detected by polymerase chain reaction testing of liver 
tissue and/or serum, even if antibody to HCV (anti-HCV) was not 
detectable,  particularly if I generation tests were used.  
 HCV increases the risk for HCC probably by promoting fibrosis 
and cirrhosis; virtually all HCV-related HCC cases occur among patients 
with cirrhosis. With the exception of areas in the world where hepatitis B 
is endemic, it is uncommon to find HCC in the absence of cirrhosis. 
 The duration of HCV infection is especially relevant to HCC 
development, with most cases of HCC occurring after 25 to 30 years of 
chronic infection .This long period probably reflects the time needed for 
the development of cirrhosis. HCV infection is a more important factor 
than HBV in the development of HCC in western countries.  
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 Markers of HCV infection are found in a higher proportion of HCC  
patients than that in most of the Asian countries; ranging  from 44% to 
66% in Italy, 27% to 58% in France, 60%  to 75% in Spain, Japan, unlike 
other Asian countries also has a high proportion of HCC caused by HCV 
infection accounting for 80% to 90% of all the cases. HCC risk increases 
to 17-fold in HCV-infected patients compared with HCV-negative 
subjects. The risk of HCC occurrence is different among all HCV 
patients. It is a function of the degree of liver fibrosis and the time of  
acquisition of the infection. The risk for cirrhotic HCV  patients (F4) was 
the highest with 5.8% per year, compared  to those who had less fibrosis 
(F1-3, 0.5% to 2.6%) .Because of the absence of reverse transcription 
activity of the HCV RNA virus, its viral genome unlike HBV is  not able 
to integrate into the genome of the infected cell. Therefore, HCV causes 
HCC via an indirect pathway by causing chronic inflammation, cell 
death, proliferation and cirrhosis.(81) HCV-related HCCs are almost 
exclusively found in patients with cirrhosis. Studies raising the possibility 
that HCV - operate through other pathways in promoting malignant 
transformation of hepatocytes.  
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Co-infection with HIV 
 Studies indicated that HCV/HIV coinfection is associated with an 
increased risk for cirrhosis as compared with patients with HIV who are 
not coinfected, (54). 
 Two studies in HCV-infected patients with hemophilia - 
nonsignificant trend toward lower rates of HCC in patients with 
coinfection as compared with those infected only with HCV.(75) 
 Patients co-infected with HIV and either hepatitis B or hepatitis C 
may have more rapidly progressive liver disease and when they reach 
cirrhosis they are also at increased risk of HCC. The MORTAVIC study 
indicated that HCC was responsible for 25% of all liver deaths in the 
post-HAART era.(74) 
Treated chronic HBV and HCV infections 
 There is no convincing evidence that interferon treatment of 
chronic hepatitis B reduces the incidence of HCC. sA meta-analysis 
conducted in patients with chronic HCV infection concluded that the 
benefit with interferon treatment was mainly seen in those who achieved 
sustained virological response, however the effect was small. The steps 
required to initiate the carcinogenic pathway probably occur many years 
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before the disease becomes inactive, and so the threat of HCC remains 
even if fibrosis decreases. Regressed fibrosis is not a rationale to withhold 
surveillance.29 
Cirrhosis and HCC 
 Most often HCC occurs within an established background of 
chronic liver disease and cirrhosis (70%–90% of all detected HCC 
cases)(31). Major causes of cirrhosis in patients with HCC include 
hepatitis B, hepatitis C, alcoholic liver disease, and possibly nonalcoholic 
steatohepatitis. Less common causes include hereditary 
hemochromatosis, alpha-1 antitrypsin deficiency, autoimmune hepatitis, 
and some porphyrias. Cirrhosis is macro nodular and is attributed to 
chronic HBV infection in Chinese and African populations, whereas in 
others, cirrhosis is commonly mixed macro nodular and micro nodular. 
Micro nodular cirrhosis may results from chronic HCV infection, alcohol 
abuse, or both. Cirrhosis contributes to hepatocarcinogenesis mainly by 
acting as a potent tumor promoter. Male sex, age, and duration of 
cirrhosis are the major risk factors for Hepatocellular carcinoma in 
cirrhotic patients. 
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Alcohol Consumption  
HCV infection and alcohol induced liver disease are both risk factors for 
HCC, although the former seems to be the more predominant risk factor.  
Presumably, they operate together to increase the risk for HCC by more 
actively promoting cirrhosis. Studies that compared development of HCC 
among HCV infected patients with the development of HCC persons with 
non-cirrhotic liver disease or controls have found only a modest effect of 
alcohol (mostly heavy alcohol use of more than 50 g/d). For example, a 
recent study by Donato et al.  reported that among alcohol drinkers, the 
risk for HCC increased in a linear fashion with a daily intake greater than 
60 g, and that the presence of HCV had a positive synergistic action with 
an additional 2-fold increase in the risk over that caused by alcohol alone. 
In addition, the proportion of patients testing positive for anti-HCV 
increased significantly among heavy drinkers with severe liver disease 
(cirrhosis or HCC) as compared with those with mild or no disease. 
The “Classic Triad” 
 In clinical practice, HCC often present with the triad of right upper 
quadrant abdominal pain, weight loss, and hepatomegaly.(68) Patients 
with these symptoms at presentation usually have a tumor larger than 6 
cm. The pain is a dull continuous ache that intensifies late in the course of 
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the illness due to involvement of Glisson’s capsule. The pain may be 
referred to the shoulder. Firm, often massive, nodular hepatomegaly is an 
invariable feature of symptomatic HCC. An arterial vascular bruit due to 
increased vascularity may be a useful diagnostic pointer. Observed in 
25% of cases, occurs in systole, rough in character, and is not affected by 
changing the position.  
Tumor Rupture: “Hemoperitoneum” 
Spontaneous rupture is a rare and catastrophic complication of 
HCC that may occur if a large vascular tumor on the periphery of the 
liver. The clinical presentation is that of severe abdominal pain, vascular 
collapse, and signs of peritoneal irritation. Hemoperitoneum is a frequent 
event late in the course of the disease, it is a presenting feature in less 
than 5% of cases. The diagnosis is established by paracentesis, which 
reveals bloodstained fluid. Angiography and embolization of the bleeding 
vessel can be an effective method for managing this life threatening 
complication.  
Extra hepatic Endocrine and Paraneoplastic Syndromes 
These systemic sequelae result from synthesis and secretion of 
biologically active substances by the tumor. Less than 5% of patients 
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results in hypoglycemia. Type A hypoglycemia is a milder form of 
glycopenia that occurs in the terminal stages of Hepatocellular carcinoma 
due to increased demands for glucose by a large rapidly growing tumor. 
Type B hypoglycemia is believed to result from the defective processing 
by malignant hepatocytes of the precursor to insulin-like growth factor II 
(pro-IGF-II).  
 Polycythemia (<10% of patient) is caused by synthesis of 
erythropoietin by the tumor.  Patients with sclerosing type of HCC may 
present with hypercalcemia in the absence of osteolytic metastases. 
Arterial hypertension complicating HCC is the consequence of ectopic 
synthesis of angiotensinogen by malignant hepatocytes. Feminization 
results from the tumor’s conversion of circulating 
dehydroepiandrosterone to estrone. Hypercholesterolemia is the result of 
de novo synthesis of cholesterol by the tumor. Watery diarrhea is 
occasionally severe and intractable, probably is related to secretion of 
peptides that promote intestinal secretion such as vasoactive intestinal 
peptide, gastrin, and prostaglandins. Cutaneous manifestations are not 
specific for the diagnosis of HCC. It includes dermatomyositis, 
pemphigus foliaceus, sign of Leser-Trelat, pityriasis rotunda, and 
porphyria cutanea tarda. 
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Paraneoplastic Syndromes Associated With HCC(77) 
¾ Hypoglycemia 
¾ Polycythemia (erythrocytosis) 
¾ Hypercalcemia 
¾ Sexual changes: isosexual precocity, gynecomastia, 
feminization 
¾ Systemic arterial hypertension 
¾ Watery diarrhea syndrome 
¾ Carcinoid syndrome 
¾ Osteoporosis 
¾ Hypertrophic osteoarthropathy 
¾ Thyrotoxicosis 
¾ Hypercholesterolemia 
¾ Thrombophlebitis migrans 
¾ Polymyositis Neuropathy 
¾ Cutaneous manifestations: pityriasis rotunda, Leser-Trelat 
sign, dermatomyositis, 
¾ Pemphigus foliaceus, porphyria  
¾ cutanea tarda 
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Serum Alfa-fetoprotein  
 First one described α-fetoprotein (AFP). is more helpful.  AFP is a 
glycoprotein that normally is produced during gestation by the fetal liver 
and yolk sac. Normally, it is present in high concentration in the fetal 
serum. AFP is elevated in 60– 70% of patients with HCC. The normal 
range of this serum marker is 0–10 ng/mL, and levels more than 400 
ng/mL are diagnostic of HCC(39). False-positive results may be caused 
by acute and chronic benign hepatic diseases with a high necro 
inflammatory activity, germ cell tumors, or pregnancy. The sensitivity, 
specificity, and positive predictive value of AFP in three well-performed 
screening studies for HCC ranged from 39 to 64%, 76 to 91%, and 9 to 
32%, respectively. 
 Alfa-fetoprotein (AFP) is a fetal glycoprotein whose circulating 
level quickly decreases after birth to 10 ng/ml. About 30–70% of HCCs 
produce AFP causing an elevation in plasma levels; in 50% of these 
cases, AFP levels are directly proportional to cancer size . Moreover, 
AFP levels tend to parallel the tumor volume doubling time . An elevated 
AFP is an established predictor of recurrence after resection  and reflects 
a poor prognosis . A fucosylated variant of AFP, the so-called Lens 
culinaris agglutinin A-reactive AFP, correlates with cancer infiltrative 
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growth, vascular invasion, low-grade differentiation, multiple cancer 
recurrence and poor prognosis..  
 AFP production is age-related. Younger patients are more likely to 
have raised levels and to attain very high concentrations. Because of both 
false-positive and false-negative results, serum AFP falls short of being 
an ideal tumor marker. 
 Several attempts made to improve the HCC specificity of AFP by 
measuring particular glycoforms of the protein. These isoforms have 
differential affinities for lectins such as Lens culinaris agglutinin and 
concanavalin A. Lens culinaris-reactive AFP, also known as AFP-L3, 
may be superior to total AFP as a marker of HCC.  
Diagnostic Imaging 
 Once a screening test is abnormal or there is a clinical suspicion 
that a patient may have HCC, imaging is very important for the diagnosis 
and staging of this tumor.  
Ultrasonography 
 Ultrasonography often used as a screening method for high-risk 
patients and is repeated at frequent intervals. A small HCC may be 
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hypoechoic, hyperechoic, or isoechoic on USG The ultrasonographic 
appearance is influenced by the presence of fat, calcium, and 
necrosis(80). Advantages of USG include safety, availability, and cost 
effectiveness, though it is operator dependent. Approximately two thirds 
of symptomatic HCC are uniformly hyperechoic, whereas the remainder 
is partly hyperechoic and partly hypoechoic. Ultrasonography with 
Doppler technology is useful for assessing the patency of the inferior 
vena cava, portal vein and its larger branches, hepatic veins, and biliary 
tree. 
CT scan and MRI 
 The most reliable diagnostic tests are triple-phase helical CT and 
triple-phase dynamic contrast enhanced magnetic resonance imaging 
(MRI)(37). HCC derives its blood supply predominantly from the hepatic 
artery, whereas the remainder of the nontumorous liver receives both 
arterial and portal blood. The hallmark of HCC during CT scan or MRI is 
the presence of arterial enhancement followed by delayed hypointensity 
of the tumor in the portal venous and delayed phases .The presence of 
arterial enhancement followed by washout has a sensitivity and 
specificity of 90% and 95%, respectively. However, 71% of patients with 
HCC will have arterial enhancement and whereas the rest do not have 
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these features and, therefore, will require liver biopsy for the diagnosis of 
HCC.  
 Studies show that MRI is slightly better in the characterization and 
diagnosis of HCC when compared with CT scan(106). The performance 
of CT and MRI is affected by the size of the lesions. Tumors larger than 2 
cm, MRI are reported to have accuracy >90%; however, in tumors 
smaller than 2 cm, this level is reduced to 33%. 
Treatment for HCC 
Liver transplantation  
 Liver transplantation is done to replace the diseased liver with a 
cadaveric liver or a living donor graft. OLT is the best treatment option 
for HCC because it eliminates the tumor together with the entire diseased 
liver, thereby eliminating the risk for development of de novo HCC. In 
the early 1990s the results of OLT for HCC were dismal, with 1-year 
survival rates of 10% to 70% and 3-year recurrence rates up to 69%(24). 
Mazzaferro and colleagues published a landmark paper on OLT for HCC. 
When OLT was restricted to patients who had a single tumor of 5 cm or 
less and no more than three tumors, each less than 3 cm in diameter, the 
4- year survival rate was 75%, and the recurrence-free survival rate was 
83%(15). For the 35 patients (73%) who met the predefined criteria, the 
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overall and recurrence-free survival rates were 85% and 92%, 
respectively. In the 13 patients (27%) who had tumors exceeding the 
criteria, the overall survival rate was 50%, and the recurrence-free 
survival rate was 59%.(28)  
 The United Network  for Organ Sharing (UNOS) has adopted these 
criteria. The number of available donors worldwide and therefore only a 
finite number of transplantations for HCC will be performed. In addition, 
waiting time for liver transplants is increasing worldwide, from 6 months 
to more than a year. Therefore, some patients will not be able to proceed 
to OLT because of tumor progression or deterioration in medical 
condition. In the United States, patients who have HCC receive higher-
ranking scores to shorten their waiting time and to prioritize them.  
 During 1996–2001 the rate had improved to 61.1%, likely related 
to adoption of the Milan criteria at US transplantation centers. Expanded 
Shanghai criteria in China resulted in overall survival and disease-free 
survival rates similar to the Milan criteria. Studies from the late 2000 
obtained higher survival rates ranging from 67% to 91%.  If the liver 
tumor has metastasized, the immunosuppressant post-transplant drugs 
decrease the chance of survival. Considering this objective risk in 
conjunction with the potentially high rate of survival, some recent studies 
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conclude that: "LTx can be a curative approach for patients with 
advanced HCC without extrahepatic metastasis"(51,52) For those reasons, 
and others, it is considered nowadays that patient selection is a major key 
for success.[52) 
Receptor tyrosine kinase 
 A new receptor tyrosine kinase inhibitor, Sorafenib  used in 
patients with advanced hepatocellular carcinoma. Sorafenib is a 
small molecule that inhibits tumor-cell proliferation and tumor 
angionesis(91,92). Spanish phase III shows- adds two months to the 
lifespan of late stage HCC patients with well preserved liver function. It 
also increases the rate of apoptosis in other tumor models. The results 
indicated that single-agent sorafenib might have a beneficial therapeutic 
effect.  
Surgical resection  
 Surgical resection to remove a tumor together with surrounding 
liver tissue while preserving enough liver remnant for normal body 
function(18). This treatment offers the best prognosis for long-term 
survival, but unfortunately only 10-15% of patients are suitable for 
surgical resection. This is often due to extensive disease or poor liver 
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function. Resection in cirrhotic patients carries high morbidity and 
mortality(22). The expected liver remnant should be more than 25% of 
the total size for a non-cirrhotic liver, while that should be more than 40% 
of the total size for a cirrhotic liver. The overall recurrent rate after 
resection is 50-60%.(23) 
Percutaneous ethanol injection  
 Percutaneous ethanol injection (PEI) well tolerated, high RR in 
small (<3 cm) solitary tumors;(85) as of 2005, no randomized trial 
comparing resection to percutaneous treatments; recurrence rates similar 
to those for post resection(21). However a comparative study found that 
local therapy can achieve a 5-year survival rate of around 60% for 
patients with small HCC.(19,29)  
Transcatheter arterial chemoembolization -(TACE)  
 Transcatheter arterial chemoembolization (TACE) is usually 
performed for unresectable tumors or as a temporary treatment while 
waiting for liver transplant(33). TACE is done by injecting an 
antineoplastic drug (e.g. cisplatin) mixed with a radioopaque contrast 
(e.g. Lipiodol) and an embolic agent (e.g. Gelfoam) into the right or left 
hepatic artery via the groin artery(86,87). By 2005, multiple trials show 
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objective tumor responses and slowed tumor progression; greatest benefit 
seen in patients with preserved liver function, absence of vascular 
invasion, and smallest tumors. TACE is not suitable for big tumors 
(>8 cm), presence of portal vein thrombus, tumors with portal-systemic 
shunt and patients with poor liver function. 
Radiofrequency ablation 
 Radiofrequency ablation (RFA) uses high frequency radio-waves 
to destroy tumor by local heating. The electrodes are inserted into the 
liver tumor under ultrasound image guidance using percutaneous, 
laparoscopic or open surgical approach. It is suitable for small tumors 
(<5 cm). A large randomised trial comparing surgical resection and RFA 
for small HCC showed similar 4 years-survival and less morbidities.[28] 
Radiation therapy 
 Selective internal radiation therapy can be used to destroy the 
tumor from within. Currently two products available,(88) SIR-
Spheres and Thera Sphere The latter is an FDA approved treatment for 
primary liver cancer (HCC) which has been shown in clinical trials to 
increase survival rate of low-risk patients. SIR-Spheres are FDA 
approved for the treatment of metastatic colorectal cancer but outside the 
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US SIR-Spheres are approved for the treatment of any non-resectable 
liver cancer including primary liver cancer. 
 This method uses a catheter (inserted by a radiologist) to deposit 
radioactive particles to the area of interest. Intra-arterial iodine-131–
lipiodol administration-- Efficacy demonstrated in unresectable patients, 
those with portal vein thrombus (86). This treatment is also used as 
adjuvant therapy in resected patients (Lau at et, 1999). It can raise the 3-
year survival rate from 46 to 86%. This adjuvant therapy is in phase III 
clinical trials in Singapore and is available as a standard medical 
treatment to qualified patients in Hong Kong. 
Combined PEI and TACE can be used for tumors larger than 4 cm in 
diameter, but Italian groups have had success with larger tumours using 
TACE alone. 
High intensity focused ultrasound 
 High intensity focused ultrasound (HIFU) (not to be confused with 
normal diagnostic ultrasound) is a new technique --- uses much more 
powerful ultrasound to treat the tumor(90). This technique is still at a 
very experimental stage. 
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Hormonal therapy 
 Antiestrogen therapy with tamoxifen studied in several trials  --- 
mixed results across studies.(32) 
Adjuvant chemotherapy 
 No randomized trials showing benefit of neoadjuvant or adjuvant 
systemic therapy in HCC. 
Palliative treatment 
 Regimens that included doxorubicin, cisplatin,  fluorouracil,  
interferon,   epirubicin,   or taxol,   as  single agents or in  combination, 
have not shown any survival benefit (RR, 0%-25%). 
Cryosurgery  
 Cryosurgery is a new technique that can destroy tumors in a variety 
of sites (brain, breast, kidney, prostate, liver). Cryosurgery is the 
destruction of abnormal tissue using sub-zero temperatures(90). 
Cryosurgery involves the placement of a stainless steel probe into the 
center of the tumor. Liquid nitrogen is circulated through the end of this 
device.  
  33
 The tumor and a half inch margin of normal liver are frozen to -
190°C for 15 minutes, which is lethal to all tissues. The area is thawed for 
10 minutes and then re-frozen to -190°C for another 15 minutes. After the 
tumor has thawed, the probe is removed, bleeding is controlled, and the 
procedure is complete. The patient will spend the first post-operative 
night in the intensive care unit and typically is discharged in 3 – 5 days. 
Proper selection of patients and attention to detail in performing the 
cryosurgical procedure are mandatory in order to achieve good results 
and outcomes.       
 Frequently, cryosurgery is used in conjunction with liver resection 
as some of the tumors are removed while others are treated with 
cryosurgery.  
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MATERIALS & METHODS 
 This descriptive study was carried out in the Department of 
Medical Gastroenterology and Hepatology, Stanley Medical College, 
Chennai. This is the major referral tertiary care center available to the 
population of Tamilnadu, Pondicherry and neighboring states Andhra 
Pradesh and Karnataka. We have been conducting a prospective 
surveillance program in patients with cirrhosis with periodical (every 6 
months) clinical assessment, AFP levels and US examination of the liver, 
in order to allow early detection of HCC and to monitor the natural 
course of the liver disease, onset of complications and long-term 
outcomes. The college ethical committee approval was obtained. 
 Using these criteria a total of 201 consecutive patients with 
cirrhosis, seen in our Department between 2008 and 2011, were included 
in this study.  All patients were followed prospectively with every  
6 months ultrasound examination of the liver, clinical and laboratory 
evaluation, including serum alanine aminotransferase (ALT) and serum 
AFP levels. Serum HBV and HCV markers (hepatitis B surface antigen 
(HBsAg) and anti-HCV were also tested at inclusion and during follow-
up in all cases, partially by retrospective analysis. Abdominal ultrasound 
examination was performed with a high resolution real-time instrument   
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with standardized criteria. Upper abdominal computed tomography (CT) 
was performed in all patients with focal lesions of the liver detectable 
and/or with increased levels of AFP (above 200 ng/ml) or peripheral 
portal thrombosis during follow-up. 
Inclusion Criteria 
(1)  presence of cirrhosis, diagnosed by clinical& lab,imaging findings 
 (presence of shrunken liver, irregular margins and altered liver 
 echo texture at USG, portal hypertension) 
(2)  Presence of stage A or B disease, according to Child– Turcotte-
 Pugh, Model for End-Stage Liver Disease classification  
(3)  Absence of clinical and ultrasonographic evidence of liver cancer 
 at entry with alpha-fetoprotein (AFP) levels <200 ng/ml.   
Diagnostic criteria for HCC 
1.  Radiological criteria: two coincident imaging techniques with 
Focal lesion >2 cm with arterial hypervascularization. 
2.  Combined criteria: one imaging technique associated with AFP 
Focal lesion >2 cm with arterial hypervascularization. 
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AFP levels >200 ng/ml diagnosis of Hepatocellular carcinoma. 
Exclusion Criteria 
Patients who have been diagnosed as  
1.  Hemangioma of liver 
2.  Secondaries liver 
3.  Benign focal liver disorders 
Study protocol 
 At the time of admission a detailed history was obtained from the 
patients or care given. Their details entered in a preformed proforma 
(Annexure). They were enquired about presenting complaints, the 
duration of illness, past h/o jaundice, blood transfusion. Detailed history 
of alcoholism and status of chronic liver disease and their treatment 
details obtained. Patients were carefully examined at the time of 
admission. Various clinical parameters studied which include jaundice, 
pallor, stigmata of chronic liver disease. Enlarged liver was looked for 
along with size, surface, border and bruit. Splenomegaly, free fluid and 
neurological status were assessed. Stage of the liver disease assessed 
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based on Child-Turcotte-Pugh (CTP), Model for End-Stage Liver Disease 
(MELD) Classification 
Table 1. The Child–Pugh Classification System 
Variable Score 1 Score 2 Score 3 
Bilirubin 
(mg/dl) 
<2.0 2–3 >3.0 
Albumin (g/l) >3.5 3.5–2.8 <2.8 
PT (INR) <1.7 1.7–2.3 >2.3 
Ascites Absent Mild to moderate Severe/refractory 
Encephalopathy Absent Mild (I–II) Severe (III–IV) 
 
Model for End-Stage Liver Disease: 
 MELD uses the patient's values for serum Bilirubin, 
serum creatinine, and the international normalized ratio for prothrombin 
time (INR) to predict survival.  
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It is calculated according to the following formula:  
MELD = 3.78[log serum Bilirubin (mg/dL)] + 11.2[Log INR] + 
9.57[Log serum creatinine (mg/dL)] + 6.43 
 The clinical stage and the severity of the disease were assessed 
based on Barcelona Clinic Liver Cancer stage. 
Table 2: The Barcelona Clinic Liver Cancer Staging Classification of 
patients with Hepatocellular carcinoma (5) 
Staging Performance 
status 
Tumor stage Child-Pugh 
(A)Early 0 Single <5 cm, 3 
nodes <3 cm 
A & B 
(B) Intermediate 0 Large/multinodular A & B 
(C) Advanced 1-2 Vascular invasion 
extra hepatic spread 
A & B 
(D) End-stage 3-4 Any of the above C 
 
 All the patients enrolled in the study were investigated as outlined 
in the Proforma (Annexure). Patients were subjected for radiological 
investigations including ultrasound abdomen, Contrast enhanced 
Computed tomography (CECT) abdomen or MRI, whichever is feasible. 
Blood samples were collected for viral markers such as HBsAg, anti-
HCV antibody, HIV serology, Liver function tests, and serum alpha 
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fetoprotein (AFP). Ascitic fluid collected for biochemical investigations. 
Upper GI endoscopy was done to assess the grade of varices and any 
evidence of portal hypertension. After admission, once clinical diagnosis 
was made appropriate therapy was instituted. 
Serologic testing 
 Anti-HCV was determined by second generation enzyme-linked 
immunosorbent assay and by second generation recombinant 
immunoblotting assay. Hepatitis B surface antigen was detected by 
commercially available kits. 
Statistical methods 
 The SPSS 16.0 version software was used for statistical analysis. 
The quantitative data were presented as mean±SD or median (range). The 
Kruskal–Wallis test was used to compare a continuous variable across 
different stages of tumors. The P-value<0.05 for univariate analysis and 
less than 0.1 for multivariate analysis was considered statistically 
significant. Univariate analysis by the Student’s t-test was used to 
compare age and duration and stage of cirrhosis at tumor diagnosis, as 
well as ALT and AFP behavior during follow-up and etiological factors 
of liver disease in relation to the pattern of HCC. 
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RESULTS 
Baseline characteristics  
 Two-hundred one (201) patients who fulfilled the study criteria 
were included in the present study. Table 1 reveals that the mean age was 
55 years with male female ratio of 5:1 (Figure 1). Out of 201 patients 
only 49 (24%) patients developed HCC, in a mean period of 30.2±6 
months and range of 22 –40 months. Socio-economic status was 
described in Table 2. 
Age distribution 
 The age distribution among the study population is summarized in 
Fig 2. Nearly half of the patients belong to the age group of 55 to 65 
years.  Mean age for male was 56.4± 10.6 and 48.4 ± 11 for female. 
Overall mean age was 55.1± 11. Nearly less than 10 percent of patients 
either belong to 40-50 years or more than 70 years of age. 
Clinical features at presentation 
 Among the symptoms abdominal pain and weight loss was most 
commonly observed symptoms. (Table 3, Figure 3) More than half of the 
patients had anorexia and or weight loss. The features of hepatic 
decompensation were seen in half the patients at first presentation with 
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Ascites in 52.8%, jaundice in 15.9% and hepatic encephalopathy in 3.8% 
of patients. Gastrointestinal bleed / melena present only in 1.4% patients. 
Hepatomegaly was seen in more than half the patients (67.8%) while in 
26% of cases liver was not enlarged (Table 4, figure4). The enlarged liver 
was hard in two-third cases and was firm in consistency in the remaining 
one third. Clubbing, hepatic bruit and were less common. 11(22.4%) 
patients had a Child–Pugh stage C and 18 (36.7%) stage B and stage A 
20(40.8%) cirrhosis. MELD score was 6-24 range and mean was 11.  
Table 1 Baseline characteristics of patients with HCC  
Parameters N=49 
Age (years) 
            Median (range)   
               Mean± SD 
 
55(29-85) 
55.1±11 
Sex (M : F) 41:8 
Symptom duration before HCC 
diagnosis(months) 
Median (range)  
<6 month (%)  
>6 month (%) 
 
 
5.6(4-10) 
44.9 
45.1 
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Male
41(83.6%)
Female
8(16.4%)
 
 
 
 
Figure. 1  
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Table 2: Socio-economic status 
Income Group 
(Rs/month) 
No. of cases Percentage 
<4000 29 59.2% 
4000-8000 14 28.56% 
>8000 6 12.2% 
 
Table 3: Symptomolgy of HCC 
 
Symptoms No. of patients Percentage (%) 
Abdominal Pain 39 79.6 
Loss of weight/ appetite 17 34.7 
Ascites 16 32.7 
UGI  bleeding 8 16.3 
Edema of legs 7 14.3 
Jaundice 6 12.2 
Oliguria 2 4.1 
Fever 2 4.1 
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Table 4: Physical signs of HCC 
Physical signs No. of patients Percentage (%) 
Hepatomegaly 19 38.7 
Pallor 7 14.2 
Edema 6 12.2 
Icterus 6 12.2 
Splenomegaly 5 10.2 
Hepatic bruit 4 8.6 
Clubbing 2 4 
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Hematological, biochemical and endoscopic profile  
 The biochemical investigations were mildly deranged. Serum alpha 
fetoprotein (AFP) was diagnostic (>200 ng/ml) in 27 of 49 (55.1%) 
patients; with normal AFP in 9 (18.3%) patients. The median serum AFP 
value was 786 ng/ml (range 0.04–98422). Mean AST and ALT values 
were more than two time of upper limit of normal. The mean serum 
Bilirubin was 5.4±2. More than three fourth of cases had esophageal 
varices with gastric varices of 19.1%. Nearly three fourth of cases had 
low serum albumin level of <2.8 gm. 
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Incidence and risk factors of HCC in HBV and in HCV associated 
cirrhosis 
 Seventeen (34.7%) were positive for HBsAg and 18 (36.7%) were 
positive for anti-HCV patients developed HCC . 
Table 4: Etiology of HCC. 
Etiology No. (%) 
Cryptogenic 4(8.1) 
HBV related 17(34.7) 
HCV related 18 (36.7%) 
Alcohol alone 9(18.4) 
HBV+HCV 1(2) 
Alcohol +HCV 5(10.2) 
Alcohol +HBV 3(6.1) 
Alcohol +HBV+HCV 1(2) 
 
  48
Radiological studies 
 Two different macroscopic patterns of HCC development were 
observed on the basis of US or CT findings (tumor margin, presence or 
absence of peri-nodular capsule : (1) tumor arising as a small, capsulated 
nodule, with well-defined margins and expansive growth (nodular type) 
and, (2) tumor presenting as a spreading mass not clearly defined, with 
ill-defined margins and infiltrative growth (infiltrating type).  
Very large tumors (>5 cm) were seen in 2/3 (two-third) of cases.  
 The average size of HCC was 6±4 cm. Small HCC (<2 cm lesion) 
was seen in only 6% of patients approximately (Table 6). Single lesion 
was the most common presentation of HCC observed in two-third cases. 
Three or more lesions were seen in about one-fifth of cases. During 
follow-up, HCC developed as nodular type in 37 (75.5%) patients, 
15(40.5%) with a single nodule and 22(59.5%) with two nodules, while in 
the remaining 11 (22.4%) cases the tumor developed as an aggressive and 
infiltrating mass. 
 On the other hand, male sex HBsAg positivity and dual HBsAg 
and anti-HCV positivity were significant risk factors for development of 
infiltrating but not nodular HCC. Vascular invasion of either major 
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branch of spleno-portal axis was seen in 1/5th of the patients. Main trunk 
of portal vein or its main branches were involved in 20.8% patients. The 
higher risk for infiltrative/diffuse but not for nodular HCC in patients is 
with HBV infection and with HBV/HCV coinfection. 
Table 5: Tumor characteristics of HCC patients 
 
Characteristic Patient number (%) 
Tumor size 
<3 cm 
3-5cm 
>5cm 
 
8(15.3 ) 
11(20.8) 
30(64) 
Portal vein thrombosis 
No portal vein thrombosis 
Main portal vein thrombosis 
 
37(75.5) 
12(24.4) 
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DISCUSSION 
 The age distribution of patients with HCC in the present study was 
similar to other studies in past. Studies from India have shown the 
maximum incidence of HCC in the fifth to sixth decade.  
 Our study showed that 43 percent of cases belong to 55 to 65 years 
of age. Only 10% belongs to 40 – 50 years age group. A very similar 
observation made by Saini et al (71) HCC commonly observed in male 
sex. The male preponderance is similar to other studies (68). 
 The population-based data show a male to female ratio of 3:1–
2:1(1). In our study showed male female ration of 5:1. High 
preponderance of HCC in males in our study could be due to gender bias 
in seeking medical treatment. And this could be partially explained by the 
fact that men are more likely to be infected with HBV and HCV, 
consume alcohol, smoke cigarettes, and have increased iron stores. 
Hospital based data from various studies made similar observation. (71)  
 In a series of 461 patients, HBV is the most common etiologic 
factor in Asian countries. It accounts for up to three-fourth cases of HCC, 
while HCV infection may account for 10–15% of HCC cases. HBsAg 
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positivity in our cases was 34.7%, which is comparable with other Indian 
studies (36% to 74 %). (68, 71). 
 The prevalence of anti-HCV antibody in India varies from 0.3% to 
1.8%.  
 In our case series HCV positivity noted only in 36.7% of cases.  
 Sensitivity of AFP ranges from 39% to 64%, specificity 76–91% 
and positive predictive value 9–32.  27 of our patients had elevated AFP 
values beyond diagnostic level. Others had either normal level 7 or levels 
were in non-diagnostic range. Studies available showing that, serum AFP 
is frequently elevated in patients with liver cirrhosis without HCC and 
can be normal or only moderately elevated in patients with Hepatocellular 
carcinoma. 
 The median AFP level was only 786 ng/ml in the study population 
despite advanced HCC was noted in three-fourth cases. There are some 
studies which suggest that the production of AFP depends on the size or 
the degree of differentiation of the hepatoma cells.  
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Clinical parameter comparison - study 
Clinical data SOUTH 
AFRICA
JAPAN ITALY INDIA My 
study  
Abdominal 
pain 
95 46.2 38 68 79.6 
Anorexia 25 44.7 6.7 74 34.7 
Weight loss  34 28.9 8 55 66.7 
Ascites 51 26.5 17.5 51 32.7 
Fever  
 
35 16.7 12 36 4.1 
Jaundice  28 16.7 14 35 12.2 
Variceal bleed 
 
2 7.6 4 22 16.3 
Hepatomegaly  - - 90 84 81.9 
Palpable mass   
 
92 23.3 - - 20.5 
Ankle edema - 16.8 - 37.5 12.5 
Asymptomatic  - - 38 - 2.8 
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Comparison of AFP values – study wise 
Study No, patients Duration of 
follow-up 
Mean level 
(ng/ml) 
Schwartz et 
al,2007 
102 24.2 618  
Paul et l,2007 154 36 >300 
Benvengnu et 
al,2001 
401 14 568-645 
My study 201 24-30 786 
 
 Even when lesions were single, they were large enough in most of 
the cases to rule out curative resection. Another study from a tertiary care 
center in India showed that 56% of patients with HCC had tumor size 
larger than 5cm and high incidence of vascular invasion of main portal 
vein in 24%.(110) More than half of the patients had a single tumor. 
Tumor was > 5cm in the majority (64%) of the patients. Moreover portal 
vein was thrombosed in 24% patient. 
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Radiological profile of HCC 
Characteristic   Kumar et 
al,2008(%) 
(110) 
Our study(%)  
                                                     Distribution of lesion 
RT.LOBE 48 49.2  
LT.LOBE 18 16.4  
BILOBAR 34 8.4  
                                                    SIZE OF HCC 
MEDIAN 6.4X6 6x4  
>5 CM 73 64  
<2CM 7.5 15.2  
                                                CT APPEARANCE 
HYPODENSE 42 45  
MIXED DENSITY 35 32  
HYPERDENSE 23 9  
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SUMMARY 
1.  The study includes total of 49 patients, mean age was 55.1 years 
with male female ratio of 5:1. Mean age for male was 56.4± 10.6 
and 48.4 ± 11 for female 
2.  Nearly half of the patients belong to the age group of 55 to  
 65 years.  
3.  Mean preadmission duration of illness was 5.6 months.  
4.  2/3 rd belongs to low socio economic status. 
5.  Among the symptoms abdominal pain (79.6.7%) and weight loss 
(34.7%) were most commonly observed symptoms.  
6.  Hepatic decompensation was seen in half the patients at first 
presentation with Ascites in 52.8%, jaundice in 15.9% and hepatic 
encephalopathy in 3.8% of patients.  
7.  The median serum AFP value of 786 ng/ml  (range 0.4–92625) 
observed in the study population. Diagnostic value of AFP >200 
ng/ml was present in 27 of 49 (55.1%) patients; with normal AFP 
in 9 (18.3%) patient.  
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8.  Hepatomegaly was seen in more than half the patients (67.8%) 
while in 26% of cases liver was not enlarged 
9.  11(22.4%) patients had a Child–Pugh stage C and 18 (36.7%) stage 
B and stage A 20(40.8%) cirrhosis. MELD score was 6-24 range 
and mean was 11.  
10.  Seventeen (34.7%) were positive for HBsAg and 18 (36.7%) were 
positive for anti-HCV patients developed HCC  
11.  Age above 59 years, male sex, longer duration and more advanced 
stage of cirrhosis were significant risk factors for HCC in anti-
HCV positive cirrhotic patients, while none of these variables were 
significant risk factors for HCC in HBsAg positive patients. 
12.  HBsAg positive patients -- presence of high or fluctuating serum 
AFP levels during follow-up was a significant risk factor for tumor 
development. 
13.  Mean AST and ALT values were more than two time of upper 
limit of normal. The mean serum Bilirubin was 5.4±2. 
14.  More than 3/4th of cases had esophageal varices with gastric varices 
of 19.1%.  
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15.  Nearly 3/4th of cases had low serum albumin level of <2.8 gm. 
16.  Very large tumors (>5 cm) were seen in two-third of cases. The 
average size of HCC was 6±4 cm. Small HCC (<2 cm lesion) was 
seen in only 6% of patients approximately. 
17.  HCC developed as nodular type in 37 (75.5%) patients, 15(40.5%) 
with a single nodule and 22(59.5%) with two nodules, while in the 
remaining 11 (22.4%) cases the tumor developed as an aggressive 
and infiltrating mass.  
18.  Male sex, HBsAg positivity and dual HBsAg and anti-HCV 
positivity were significant risk factors for development of 
infiltrating but not nodular HCC.  
19.  The higher risk for infiltrative/diffuse but not for nodular HCC is 
seen in patients with HBV infection and with HBV/HCV 
coinfection. 
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CONCLUSION 
1) In our study --- Age above 59 years, male sex, longer duration 
and more advanced stage of cirrhosis were significant risk 
factors for HCC in anti-HCV positive cirrhotic patients, while 
none of these variables were significant risk factors for HCC in 
HBsAg positive patients. 
2) In our study --- high AFP fetoprotein predicts early development 
of HCC in cirrhotics. 
3) In our study --- higher risk for infiltrative / diffuse but not for 
nodular HCC is seen in patients with HBV infection and with 
HBV/HCV coinfection. 
4) In our study -- mean duration of survival after the diagnosis is <9 
months. 
5) In our study -- The paraneoplastic manifestations are distinctly 
rare.  
6) In our study -- HCC is diagnosed very late and presents with 
vascular invasion or metastases in most of the cases 
7) In our study --Since HBV is one of most common etiologic agent,  
the universal  vaccination  against  hepatitis  B  would prove an 
effective preventive strategy. 
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HCV related DCLD/PHT/HCC right lobe (child A) Mr Anbalagan 52 0 22‐Sep‐08 1386/08 3000 FALSE FALSE TRUE FALSE 1 year FALSE 1 10 80 FALSE FALSE FALSE FALSE FALSE TRUE 12.8 5700 P58L32E10 280000 39.7 15/14 1.1 279 20.6 1.0 1.02/0.97 95 66 4.1/4.1 160 0 20.1 11 A 18 7.5x6.5
Cirrhosis of liver/ascites/advanced HCC right lobe Mr Chinnaswami 72 0 24‐Dec‐08 5162/08 4000 TRUE 20 days FALSE TRUE FALSE 1 month FALSE 2 10 180 FALSE FALSE TRUE FALSE FALSE FALSE 11.6 11800 P81L12E07 108000 36.5 13/17 1.4 61 39 1.13 33.9/23.6 421 252 3.5/3.4 380 0 18.4 24 B 7
HBV related DCLD/PHT/Advanced HCC/palliation Chemotherapy Mr Chinnaswami 50 0 14‐Nov‐08 47191/08 5000 FALSE FALSE TRUE FALSE 1 year FALSE 0 FALSE FALSE TRUE TRUE 1 0 TRUE FALSE 9.3 7600 P52L30E09 234000 32 15/15 1.0 176 33 0.9 1.20/0.77 92 42 3.4/3.8 121 ‐1 450 6 A 5 1.4x1
DCLD/PHD/ethanol related/HCC right lobe/post RFA Mr Krishnamurthi 85 0 25‐Nov‐08 48482/08 5000 TRUE 6 months FALSE FALSE FALSE FALSE 0 TRUE TRUE TRUE TRUE 1 0 0 FALSE FALSE 9.5 4100 P69L29E10 103000 29.4 15/15 1.0 118 25.7 0.8 2.7/1.53 100 79 3.5/4.7 422 ‐1 598 8 A 9 3x3
HBV related DCLD/PHT/HCC 6&7 child B/resection of segment 6&7 Mr Powee 55 0 18‐Aug‐08 36428/08 25000 FALSE FALSE TRUE TRUE 3 months FALSE 0 FALSE TRUE FALSE TRUE 1 0 TRUE FALSE 12 11000 P77L13E10 210000 37 15/16 1.1 77 14 1.1 3.3/2.4 84 32 2.9/4.5 244 0 64.89 13 B 8x6.5
HCV related DCLD/PHT/Advanced HCC/PVT/transient chemotherapy Mr Nataranjan 58 0 08‐Nov‐10 39732/10 8000 FALSE FALSE FALSE FALSE FALSE 0 FALSE FALSE FALSE FALSE FALSE TRUE 13.8 6800 P67L28E05 179000 43.8 15/14 1 153 26.2 0.78 1.26/0.8 56 51 4.0/2.7 240 ‐1 206.7 6 A 8
HCV related DCLD/PHT/HCC right lobe Mr Dakshinamurthy 61 0 25‐Mar‐09 10108/09 3000 FALSE FALSE FALSE FALSE FALSE 0 FALSE FALSE FALSE FALSE FALSE TRUE 12.7 9300 P60L30E10 127000 39.4 15/17 1.2 71 24 1.3 0.41/0.29 124 68 3.3/4.3 290 0 3.24 11 A 9 6.1x5.6
HCV related DCLD/PHT/Advanced HCC right lobe Mr Bhaskar 62 0 23‐Feb‐09 6442/09 3000 FALSE FALSE TRUE FALSE 2 months FALSE 1 15 180 FALSE FALSE TRUE TRUE 1 0 0 FALSE TRUE 12.8 9100 P69L23E08 196000 41.2 15/14 1.0 95 25 0.7 0.8/0.41 665 119 3.2/3.7 670 0 161 6 A 8 8x6
HCV related DCLD/PHT/HCC/PVT Mr Mathivanan 42 0 23‐Mar‐09 11862/09 4000 TRUE 3 months FALSE TRUE FALSE 2 months FALSE 0 TRUE TRUE TRUE TRUE 1 0 1 FALSE TRUE 10.2 10500 P74L16E10 290000 32 15/18 1.3 120 11.7 0.7 3.4/2.6 282 227 2.1/5.8 386 ‐1 4553 11 B 4
HBV related DCLD/PHT/HCC with PVT left lobe Mr Murlikrishnan 57 0 09‐May‐09 15379/09 4000 FALSE FALSE TRUE FALSE 2 months FALSE 0 TRUE FALSE FALSE TRUE 0 0 0 TRUE FALSE 11.7 13300 P70L28E02 335000 36.6 15/15 1.0 100 29 1.4 0.4/0.3 26 07 3/4.8 377 ‐1 1086 10 A 12
HCV related DCLD/PHT/bilobar HCC with PVT Mr Parchigam 49 0 30‐Jan‐09 3346/09 3000 TRUE 1 month TRUE TRUE FALSE 1 month FALSE 0 FALSE TRUE TRUE TRUE 1 0 1 FALSE TRUE 13.1 5900 P60L30E10 161000 42.2 15/14 1.0 114 15.7 1.2 3.1/2.2 100 93 3.4/3.6 46 ‐1 786 12 B 5
HCV related DCLD/PHT/HCC RFA done Mrs Pappamal 48 1 18‐Feb‐09 5743/11 2000 FALSE FALSE TRUE TRUE 3 months FALSE 0 TRUE FALSE FALSE TRUE 0 0 1 FALSE FALSE 9.6 10000 P50L40E10 23000 28.8 15/21 1.5 196 19.7 0.5 1.0/0.81 109 69 3/3.5 502 ‐1 650.56 6 A 14 4x3.8
Ethanol related DCLD/PHT/HCC/PVT(main PV) Mr Deengaswamy 60 0 24‐Dec‐08 51650/08 5000 FALSE FALSE TRUE FALSE 1 month FALSE 2 15 180 FALSE TRUE TRUE TRUE 0 0 1 FALSE FALSE 12.1 11300 P83L03E08 358000 38 15/21 1.5 127 19.9 0.5 1.6/1.1 85 87 3.3/3.7 761 0 35.8 6 A 6
HBV related DCLD/PHT/advanced HCC Mr Gopal 58 0 06‐Feb‐09 4279/09 3000 FALSE FALSE TRUE FALSE 2 months FALSE 0 FALSE FALSE TRUE TRUE 0 0 FALSE FALSE 13 7300 P50L40E10 250000 31 15/14 1.0 70 31 0.5 1.0/0.4 122 134 3.6/4.4 305 ‐1 1134 6 A 13 6x7
HBV related DCLD/PHT/HCC left lobe Mr Govindan 56 0 12‐Feb‐09 1897/09 4000 FALSE FALSE TRUE TRUE 3 months FALSE 2 10 180 TRUE FALSE TRUE TRUE 1 0 1 TRUE FALSE 10.8 7000 P60L35E05 347000 34 15/17 1.2 87 31 0.6 1.6/0.54 86 57 2.9/3.2 868 ‐1 587 6 A 5 12.4x12
Ethanol related DCLD/PHT/advanced HCC Mr Sampath Kumar 52 0 17‐Feb‐09 5614/09 3500 FALSE FALSE TRUE FALSE 1 month FALSE 1 10 270 TRUE TRUE TRUE TRUE 1 0 FALSE FALSE 8.6 11600 P81L42E07 565000 25 14/15 1.0 150 28 1.0 2.9/1.4 308 95 2.8/4.7 1309 ‐1 60500 10 B 5
Ethanol related DCLD/PHT/HCC advanced right lobe of liver Mr Syed Ebrahim 67 0 23‐Dec‐08 51563/08 6000 TRUE 4 months TRUE TRUE FALSE 1 month FALSE 1 15 180 FALSE TRUE TRUE TRUE 1 0 1 FALSE FALSE 12.7 9100 P72L18E10 344000 40 15/15 1.0 326 28 0.6 7.3/5.0 98 56 3.2/3.4 816 ‐1 3000 9 B 5
HCV related DCLD/PHT/Cheld A/HCC right lobe Mr Anbagham 52 0 22‐Sep‐08 40558/08 3000 FALSE FALSE TRUE FALSE 1 year FALSE 2 10 180 FALSE FALSE FALSE TRUE 0 0 1 FALSE TRUE 12.8 5700 P58L32E10 280000 39.7 15/14 1.0 279 20.6 1.0 1.02/0.97 95 66 4.1/4.1 160 0 20.1 6 A 7.5x6.5
HCV related DCLD/PHT/HCC right lobe Mr Dhanasekharan 51 0 21‐Nov‐09 39743/09 10000 FALSE FALSE TRUE FALSE 1 month FALSE 0 TRUE FALSE TRUE TRUE 1 0 FALSE TRUE 7.1 1300 P45L45E10 47000 22 15/22 1.8 157 19 1.2 1.7/1.4 57 22 2.3/2.5 205 0 43.1 17 B 5
HCV related DCLD/PHT/HCC right lobe liver Mr Manikkam 59 0 04‐May‐10 15523/10 4500 FALSE FALSE TRUE FALSE 1 month FALSE 0 TRUE FALSE FALSE FALSE FALSE TRUE 10.8 7200 P60L30E10 457000 37.5 15/14 1.0 183 17.7 0.8 1.0/0.95 26 14 4.1/3.7 185 ‐1 215.71 6 A 11 1.3x1
HCV related DCLD/PHT/Multicentric HCC/old MI Mr Arulsamy 69 0 20‐Mar‐10 9992/10 5000 FALSE FALSE TRUE FALSE 15 days FALSE 0 FALSE FALSE FALSE TRUE 1 0 FALSE TRUE 12.7 9300 P60L30E10 198000 39.4 15/14 1.0 127 25.5 0.65 0.9/0.6 124 51 3.7/3.2 254 ‐1 3000 6 A 5 10x8
HCV related DCLD/PHT/HCC left lobe Mr Arumugam 60 0 09‐Dec‐10 43398/10 2000 FALSE FALSE TRUE FALSE 3 months FALSE 2 10 180 TRUE FALSE FALSE TRUE 0 0 FALSE TRUE 11.4 6900 P65L26E09 126000 35.7 15/14 1.0 112 35.4 1.06 1.2/0.69 105 78 3.6/4.9 501 0 1 8 A 9 3x1
HBV/DCLD/PHT/HCC right lobe Mrs Parimala 60 1 28‐Feb‐11 7426/11 TRUE 2 months FALSE FALSE FALSE FALSE 0 TRUE FALSE TRUE TRUE 1 0 1 TRUE FALSE 9.7 6900 P76L17E07 223000 29.9 14/19 1.4 123 17.0 0.9 0.74/0.55 66 40 2.3/7.9 210 ‐1 686 8 A 6 9.2x9
DCLD/PHT/multifocal HCC/BCS Mrs Chinnapappa 35 1 07‐Dec‐10 20313/10 2000 FALSE FALSE TRUE FALSE 6 months FALSE 0 TRUE FALSE TRUE TRUE 0 0 0 FALSE FALSE 7.5 6900 P65L26E09 113000 39.2 15/14 1.0 119 23.4 0.82 0.71/0.34 57 32 3.8/4.3 327 ‐1 >1000 6 A 9 6.7x5
HCV related DCLD/PHT/HCC right lobe Mr Krishnamoorthy 76 0 26‐Nov‐10 42013/10 2000 TRUE 1 month FALSE TRUE FALSE 2 months FALSE 0 TRUE FALSE TRUE TRUE 1 1 1 FALSE TRUE 8.9 13500 P72L20E08 91000 46.1 15/14 1.0 117 47.4 1.12 1.3/0.9 25 29 2.4/3.6 137 ‐1 768 9 A 8 8x6.4
HBV related DCLD/PHT/Multicentric HCC/SHT/CAHD Mrs Malliya 56 1 21‐Jan‐10 2517/10 1500 FALSE TRUE FALSE TRUE FALSE 0 TRUE TRUE FALSE TRUE 1 0 1 TRUE FALSE 10.8 2900 P75L16E09 44000 34.1 15/16 1.0 99 32 1.0 1.2/1.0 27 97 2.5/3.3 332 0 12.8 7 A 9
HCV related DCLD/PHT/Multicentric HCC Mr Maran 55 0 19‐Jul‐10 25269/10 3000 FALSE FALSE TRUE FALSE 2 months FALSE 2 10 180 FALSE FALSE FALSE TRUE 1 1 1 FALSE TRUE 15.6 13500 P72L20E08 166000 46.1 15/14 1.0 160 31.3 0.77 1.0/0.6 25 29 4.4/2.7 206 ‐1 592 6 A 7
Ethanol related DCLD/PHT/HCC Mr Venkateshaw 45 0 09‐Jan‐10 1106/10 3000 FALSE FALSE TRUE FALSE 6 months FALSE 2 15 90 TRUE FALSE FALSE TRUE 0 0 1 FALSE FALSE 10.9 5900 P72L20E08 106000 32 14/15 1.0 268 19 0.44 1.2/0.8 79 57 2.6/4.7 402 ‐1 851 6 A 13 7.3x6.1
Ethanol related DCLD/PHT/HCC
Mr Kalyana 
Sundaram
71 0 30‐Dec‐10 45656/10 3000 TRUE 6 months FALSE FALSE FALSE FALSE 2 10 180 TRUE FALSE TRUE FALSE FALSE FALSE 4.7 3600 P66L19E10 138000 16.9 14/16 1.2 150 26.3 0.85 7.2/5.6 57 25 3.4/2.8 229 0 4 14 B 9 5.8x5.7
HBV related DCLD/PHT/Advanced HCC/PVTright lobe Mrs Nasima 30 1 03‐Jan‐11 271/11 FALSE FALSE TRUE FALSE 1 month FALSE 0 TRUE FALSE TRUE TRUE 1 0 1 TRUE FALSE 7.3 4400 P66L20E10 148000 27.3 15/14 1.0 116 19.2 0.47 1.28/0.8 107 32 3.4/4.2 338 ‐1 300000 6 A 5
13.7x12.
8
HBV related DCLD/PHT/Advanced HCC Mr Ibrahim 47 0 15‐Jul‐11 24817/10 3000 FALSE FALSE TRUE FALSE 1 month FALSE 2 10 180 FALSE FALSE FALSE TRUE 0 0 1 TRUE FALSE 13.3 8500 P71L21E08 394000 44.9 15/14 1.0 112 16.5 0.84 1.0/0.6 111 47 3.6/3.7 218 ‐1 605000 6 A 8 9.4x6.5
HBV related DCLD/PHT/HCC right lobe Mr Pedhutu 29 0 13‐Aug‐09 27327/09 4000 FALSE FALSE TRUE TRUE 2 months FALSE 0 FALSE FALSE FALSE FALSE TRUE FALSE 16 8600 P65L31E04 305000 50.9 15/14 1.0 64 22 0.8 1.2/0.9 20 66 3.4/3,1 2073 0 70.7 6 A 6 20x20
HBV related DCLD/PHT/Bilobar Multicentric HCC Mrs Tamilarasi 50 1 12‐Nov‐10 40242/10 FALSE FALSE TRUE TRUE 4 months FALSE 0 TRUE FALSE FALSE TRUE 1 0 1 TRUE FALSE 12.3 10400 P75L20E10 352000 42.7 15/15 1.0 73 20 0.8 1.4/0.87 135 135 3.3/3.1 1812 0 12.2 6 A 6
HCV related DCLD/PHT/HCC Mr Raman 70 0 16‐Nov‐10 40785/10 FALSE FALSE TRUE FALSE 6 months FALSE 2 15 180 TRUE FALSE FALSE TRUE 1 0 1 FALSE TRUE 11 8200 P69L25E06 392000 34 14/14 1.0 492 30.1 0.9 0.79/0.33 109 33 3.6/3.2 2961 0 0.2 6 A 12
13.5x11.
7
HBV related DCLD/PHT/Advanced HCC Mr Chella Durai 47 0 15‐Apr‐11 12869/11 3000 TRUE 6 months FALSE TRUE TRUE 1 year FALSE 0 TRUE TRUE TRUE TRUE 0 0 1 TRUE FALSE 11.1 6200 P64L24E10 114000 36.5 15/14 1.0 92 19.1 0.7 2.1/1.0 200 183 3.5/3.9 1526 ‐1 986 6 A 3
Ethanol related DCLD/PHT/multicentric HCC/child B Mr Kalliyannan 61 0 03‐Jan‐11 221/11 3000 FALSE FALSE TRUE TRUE 3 years FALSE 0 FALSE FALSE FALSE TRUE 1 0 1 FALSE FALSE 7.5 5300 P71L21E08 85000 27.3 15/15 1.1 95 21 0.6 0.9/0.55 39 27 2.8/3.9 267 0 1.35 6 A 4 5x4
Ethanol related DCLD/PHT/HCC Mr Pardaram 48 0 07‐Nov‐09 38016/09 3000 TRUE 1 month FALSE TRUE TRUE 1 month FALSE 1 10 180 TRUE TRUE TRUE TRUE 1 0 1 FALSE FALSE 11.2 8600 P80L10E10 133000 36.6 15/17 1.3 80 30.2 0.8 6.1/4.0 128 48 1.9/3.2 1128 0 5.28 14 B 4
HBV related DCLD/PHT/HCC/locally advanced Mr Sekhar 44 0 31‐Dec‐09 44779/09 5000 FALSE FALSE TRUE TRUE 3 months FALSE 1 10 180 TRUE FALSE FALSE TRUE 1 0 0 TRUE FALSE 11.9 11900 P74L16E10 430000 40.4 15/16 1.1 125 17.8 0.8 1.5/1.1 54 30 3.5/2.6 928 ‐1 >3000 7 A 10 11.5x7.2
HBV related DCLD/PHT/HCC right lobe Mrs Vellachi 48 1 13‐Jul‐10 24520/10 FALSE FALSE TRUE FALSE 1 month FALSE 0 TRUE FALSE FALSE TRUE 0 0 0 TRUE FALSE 11.3 7000 P65L25E10 309000 37.9 15/14 1.0 139 22.3 0.75 0.9/0.5 100 56 2.8/2.5 214 ‐1 >3000 6 A 10.5x9.5
HCV related DCLD/PHT/HCC right lobe Mr Mannikam 59 0 19‐May‐10 2470/10 11000 FALSE TRUE TRUE TRUE 1 month FALSE 2
occas
ional
FALSE TRUE FALSE FALSE FALSE TRUE 10.8 7200 P60L30E10 457000 32.2 14/26 1.2 183 17.7 0.8 1.0/0.95 26 14 4.1/3.7 185 ‐1 215.71 6 A 4
MASTER CHART 
Ethanol related DCLD/PHT/HE/type 2 DM/HCC Mr Padmanabham 72 0 23‐Apr‐11 2169/11 5000 TRUE 6 months FALSE FALSE FALSE FALSE 2 7 TRUE FALSE FALSE FALSE TRUE FALSE 12.9 8200 P80L09E11 90000 40.9 14/16 1.1 106 33.94 0.76 1.2/0.8 109 31 2.3/2.4 263 ‐1 705 6 A 8.5x8.1
HCV related DCLD/PHT/SBP/HCC/PVT Mr Jhukkanam 48 0 28‐Jan‐11 225/11 2500 TRUE 3 months TRUE TRUE FALSE 2 months FALSE 2 13 180 TRUE TRUE FALSE TRUE 0 0 FALSE TRUE 14 11100 P70L20E10 146000 42.7 14/15 1.0 194 41.2 0.56 3.4/1.9 216 63 3.5/3.4 555 ‐1 11435 6 A
HCV related DCLD/PHT/DM/HCC Mr Ramagle 47 0 11‐Jan‐11 499/11 12000 FALSE FALSE TRUE FALSE 3 months FALSE 0 FALSE FALSE FALSE TRUE 1 0 0 FALSE TRUE 13.9 10100 P65L25E10 281000 43.1 14/22 1.9 95 11.7 0.6 0.8/0.5 36 39 2.9/3.6 431 ‐1 435.6 7 A 4
HBV related DCLD/PHT/PVT/PCC Mr Mohandas 55 0 26‐Jan‐11 246/11 FALSE FALSE FALSE TRUE FALSE 0 FALSE FALSE FALSE TRUE 1 1 TRUE FALSE 10.7 11400 P81L10E09 145000 35.3 15/18 1.3 155 23.82 0.64 1.59/0.99 71 25 2.7/4.7 500 256 6 A 6.9x7.1
HBV related DCLD/PHT/HCC/non alcoholic Mrs Parimala 60 1 12‐Jan‐11 319/11 TRUE 1 month FALSE FALSE TRUE FALSE 0 TRUE FALSE FALSE TRUE 1 0 1 TRUE FALSE 9.2 6900 P67L20E13 255000 29.1 15/17
26/2
8
286 10.33 0.63 1.25/0.66 69 37 2.1/4.7 209 12.3 7 B 6 9.2x9
HBsAg DCLD/PHT/HCC Mr Ragu 60 0 7053/10 TRUE 3 months TRUE TRUE TRUE 2 months FALSE 0 TRUE TRUE FALSE TRUE 1 0 0 FALSE FALSE 10.2 7600 P80L20 120000 33 15/18 1.3 176 30.4 0.9 1.0/0.8 56 48 2/3.2 308 392 14 A 7
HBV related DCLD/PHT/HCC Mr Mahadevan 56 0 149/09 TRUE 3 months FALSE FALSE TRUE FALSE 0 FALSE FALSE FALSE TRUE 0 0 0 TRUE FALSE 9.2 3800 P74L18 85000 32 19 1.3 74 14 0.7 1.4/0.8 63 32 2.1/4.7 190 0.4 6 A 7 8.1x8
HBV related DCLD/PHT/HCC Mr Sundaraj 42 0 3012/10 FALSE FALSE TRUE TRUE 6 months FALSE 2 8 180 TRUE FALSE FALSE TRUE 0 0 0 TRUE FALSE 16.3 7000 P60L30E10 171000 51.3 16 1.2 85 23.3 0.91 1.4/1.0 410 83 3.3/3.8 467 3000 6 B 7
HCV related DCLD/PHT/PVT/multicentric HCC
Mr 
Balasubhramaniam
56 0 09‐Mar‐10 1254/10 TRUE 2 months FALSE TRUE TRUE 1 week FALSE 0 FALSE FALSE FALSE TRUE 1 0 0 FALSE TRUE 13.1 6400 P80L13E07 14000 41.1 18 1.3 95 41.1 0.68 5.2/3.7 17 126 2.5/3.9 697 721.67 6 A 9 4.1x3.4
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HCV related DCLD/PHT/HCC right lobe (child A) Mr Anbalagan 52 0 22‐Sep‐08 1386/08 3000 FALSE FALSE TRUE FALSE 1 year FALSE 1 10 80 FALSE FALSE FALSE FALSE FALSE TRUE 12.8 5700 P58L32E10 280000 39.7 15/14 1.1 279 20.6 1.0 1.02/0.97 95 66 4.1/4.1 160 0 20.1 11 A 18 7.5x6.5
Cirrhosis of liver/ascites/advanced HCC right lobe Mr Chinnaswami 72 0 24‐Dec‐08 5162/08 4000 TRUE 20 days FALSE TRUE FALSE 1 month FALSE 2 10 180 FALSE FALSE TRUE FALSE FALSE FALSE 11.6 11800 P81L12E07 108000 36.5 13/17 1.4 61 39 1.13 33.9/23.6 421 252 3.5/3.4 380 0 18.4 24 B 7
HBV related DCLD/PHT/Advanced HCC/palliation Chemotherapy Mr Chinnaswami 50 0 14‐Nov‐08 47191/08 5000 FALSE FALSE TRUE FALSE 1 year FALSE 0 FALSE FALSE TRUE TRUE 1 0 TRUE FALSE 9.3 7600 P52L30E09 234000 32 15/15 1.0 176 33 0.9 1.20/0.77 92 42 3.4/3.8 121 ‐1 450 6 A 5 1.4x1
DCLD/PHD/ethanol related/HCC right lobe/post RFA Mr Krishnamurthi 85 0 25‐Nov‐08 48482/08 5000 TRUE 6 months FALSE FALSE FALSE FALSE 0 TRUE TRUE TRUE TRUE 1 0 0 FALSE FALSE 9.5 4100 P69L29E10 103000 29.4 15/15 1.0 118 25.7 0.8 2.7/1.53 100 79 3.5/4.7 422 ‐1 598 8 A 9 3x3
HBV related DCLD/PHT/HCC 6&7 child B/resection of segment 6&7 Mr Powee 55 0 18‐Aug‐08 36428/08 25000 FALSE FALSE TRUE TRUE 3 months FALSE 0 FALSE TRUE FALSE TRUE 1 0 TRUE FALSE 12 11000 P77L13E10 210000 37 15/16 1.1 77 14 1.1 3.3/2.4 84 32 2.9/4.5 244 0 64.89 13 B 8x6.5
HCV related DCLD/PHT/Advanced HCC/PVT/transient chemotherapy Mr Nataranjan 58 0 08‐Nov‐10 39732/10 8000 FALSE FALSE FALSE FALSE FALSE 0 FALSE FALSE FALSE FALSE FALSE TRUE 13.8 6800 P67L28E05 179000 43.8 15/14 1 153 26.2 0.78 1.26/0.8 56 51 4.0/2.7 240 ‐1 206.7 6 A 8
HCV related DCLD/PHT/HCC right lobe Mr Dakshinamurthy 61 0 25‐Mar‐09 10108/09 3000 FALSE FALSE FALSE FALSE FALSE 0 FALSE FALSE FALSE FALSE FALSE TRUE 12.7 9300 P60L30E10 127000 39.4 15/17 1.2 71 24 1.3 0.41/0.29 124 68 3.3/4.3 290 0 3.24 11 A 9 6.1x5.6
HCV related DCLD/PHT/Advanced HCC right lobe Mr Bhaskar 62 0 23‐Feb‐09 6442/09 3000 FALSE FALSE TRUE FALSE 2 months FALSE 1 15 180 FALSE FALSE TRUE TRUE 1 0 0 FALSE TRUE 12.8 9100 P69L23E08 196000 41.2 15/14 1.0 95 25 0.7 0.8/0.41 665 119 3.2/3.7 670 0 161 6 A 8 8x6
HCV related DCLD/PHT/HCC/PVT Mr Mathivanan 42 0 23‐Mar‐09 11862/09 4000 TRUE 3 months FALSE TRUE FALSE 2 months FALSE 0 TRUE TRUE TRUE TRUE 1 0 1 FALSE TRUE 10.2 10500 P74L16E10 290000 32 15/18 1.3 120 11.7 0.7 3.4/2.6 282 227 2.1/5.8 386 ‐1 4553 11 B 4
HBV related DCLD/PHT/HCC with PVT left lobe Mr Murlikrishnan 57 0 09‐May‐09 15379/09 4000 FALSE FALSE TRUE FALSE 2 months FALSE 0 TRUE FALSE FALSE TRUE 0 0 0 TRUE FALSE 11.7 13300 P70L28E02 335000 36.6 15/15 1.0 100 29 1.4 0.4/0.3 26 07 3/4.8 377 ‐1 1086 10 A 12
HCV related DCLD/PHT/bilobar HCC with PVT Mr Parchigam 49 0 30‐Jan‐09 3346/09 3000 TRUE 1 month TRUE TRUE FALSE 1 month FALSE 0 FALSE TRUE TRUE TRUE 1 0 1 FALSE TRUE 13.1 5900 P60L30E10 161000 42.2 15/14 1.0 114 15.7 1.2 3.1/2.2 100 93 3.4/3.6 46 ‐1 786 12 B 5
HCV related DCLD/PHT/HCC RFA done Mrs Pappamal 48 1 18‐Feb‐09 5743/11 2000 FALSE FALSE TRUE TRUE 3 months FALSE 0 TRUE FALSE FALSE TRUE 0 0 1 FALSE FALSE 9.6 10000 P50L40E10 23000 28.8 15/21 1.5 196 19.7 0.5 1.0/0.81 109 69 3/3.5 502 ‐1 650.56 6 A 14 4x3.8
Ethanol related DCLD/PHT/HCC/PVT(main PV) Mr Deengaswamy 60 0 24‐Dec‐08 51650/08 5000 FALSE FALSE TRUE FALSE 1 month FALSE 2 15 180 FALSE TRUE TRUE TRUE 0 0 1 FALSE FALSE 12.1 11300 P83L03E08 358000 38 15/21 1.5 127 19.9 0.5 1.6/1.1 85 87 3.3/3.7 761 0 35.8 6 A 6
HBV related DCLD/PHT/advanced HCC Mr Gopal 58 0 06‐Feb‐09 4279/09 3000 FALSE FALSE TRUE FALSE 2 months FALSE 0 FALSE FALSE TRUE TRUE 0 0 FALSE FALSE 13 7300 P50L40E10 250000 31 15/14 1.0 70 31 0.5 1.0/0.4 122 134 3.6/4.4 305 ‐1 1134 6 A 13 6x7
HBV related DCLD/PHT/HCC left lobe Mr Govindan 56 0 12‐Feb‐09 1897/09 4000 FALSE FALSE TRUE TRUE 3 months FALSE 2 10 180 TRUE FALSE TRUE TRUE 1 0 1 TRUE FALSE 10.8 7000 P60L35E05 347000 34 15/17 1.2 87 31 0.6 1.6/0.54 86 57 2.9/3.2 868 ‐1 587 6 A 5 12.4x12
Ethanol related DCLD/PHT/advanced HCC Mr Sampath Kumar 52 0 17‐Feb‐09 5614/09 3500 FALSE FALSE TRUE FALSE 1 month FALSE 1 10 270 TRUE TRUE TRUE TRUE 1 0 FALSE FALSE 8.6 11600 P81L42E07 565000 25 14/15 1.0 150 28 1.0 2.9/1.4 308 95 2.8/4.7 1309 ‐1 60500 10 B 5
Ethanol related DCLD/PHT/HCC advanced right lobe of liver Mr Syed Ebrahim 67 0 23‐Dec‐08 51563/08 6000 TRUE 4 months TRUE TRUE FALSE 1 month FALSE 1 15 180 FALSE TRUE TRUE TRUE 1 0 1 FALSE FALSE 12.7 9100 P72L18E10 344000 40 15/15 1.0 326 28 0.6 7.3/5.0 98 56 3.2/3.4 816 ‐1 3000 9 B 5
HCV related DCLD/PHT/Cheld A/HCC right lobe Mr Anbagham 52 0 22‐Sep‐08 40558/08 3000 FALSE FALSE TRUE FALSE 1 year FALSE 2 10 180 FALSE FALSE FALSE TRUE 0 0 1 FALSE TRUE 12.8 5700 P58L32E10 280000 39.7 15/14 1.0 279 20.6 1.0 1.02/0.97 95 66 4.1/4.1 160 0 20.1 6 A 7.5x6.5
HCV related DCLD/PHT/HCC right lobe Mr Dhanasekharan 51 0 21‐Nov‐09 39743/09 10000 FALSE FALSE TRUE FALSE 1 month FALSE 0 TRUE FALSE TRUE TRUE 1 0 FALSE TRUE 7.1 1300 P45L45E10 47000 22 15/22 1.8 157 19 1.2 1.7/1.4 57 22 2.3/2.5 205 0 43.1 17 B 5
HCV related DCLD/PHT/HCC right lobe liver Mr Manikkam 59 0 04‐May‐10 15523/10 4500 FALSE FALSE TRUE FALSE 1 month FALSE 0 TRUE FALSE FALSE FALSE FALSE TRUE 10.8 7200 P60L30E10 457000 37.5 15/14 1.0 183 17.7 0.8 1.0/0.95 26 14 4.1/3.7 185 ‐1 215.71 6 A 11 1.3x1
HCV related DCLD/PHT/Multicentric HCC/old MI Mr Arulsamy 69 0 20‐Mar‐10 9992/10 5000 FALSE FALSE TRUE FALSE 15 days FALSE 0 FALSE FALSE FALSE TRUE 1 0 FALSE TRUE 12.7 9300 P60L30E10 198000 39.4 15/14 1.0 127 25.5 0.65 0.9/0.6 124 51 3.7/3.2 254 ‐1 3000 6 A 5 10x8
HCV related DCLD/PHT/HCC left lobe Mr Arumugam 60 0 09‐Dec‐10 43398/10 2000 FALSE FALSE TRUE FALSE 3 months FALSE 2 10 180 TRUE FALSE FALSE TRUE 0 0 FALSE TRUE 11.4 6900 P65L26E09 126000 35.7 15/14 1.0 112 35.4 1.06 1.2/0.69 105 78 3.6/4.9 501 0 1 8 A 9 3x1
HBV/DCLD/PHT/HCC right lobe Mrs Parimala 60 1 28‐Feb‐11 7426/11 TRUE 2 months FALSE FALSE FALSE FALSE 0 TRUE FALSE TRUE TRUE 1 0 1 TRUE FALSE 9.7 6900 P76L17E07 223000 29.9 14/19 1.4 123 17.0 0.9 0.74/0.55 66 40 2.3/7.9 210 ‐1 686 8 A 6 9.2x9
DCLD/PHT/multifocal HCC/BCS Mrs Chinnapappa 35 1 07‐Dec‐10 20313/10 2000 FALSE FALSE TRUE FALSE 6 months FALSE 0 TRUE FALSE TRUE TRUE 0 0 0 FALSE FALSE 7.5 6900 P65L26E09 113000 39.2 15/14 1.0 119 23.4 0.82 0.71/0.34 57 32 3.8/4.3 327 ‐1 >1000 6 A 9 6.7x5
HCV related DCLD/PHT/HCC right lobe Mr Krishnamoorthy 76 0 26‐Nov‐10 42013/10 2000 TRUE 1 month FALSE TRUE FALSE 2 months FALSE 0 TRUE FALSE TRUE TRUE 1 1 1 FALSE TRUE 8.9 13500 P72L20E08 91000 46.1 15/14 1.0 117 47.4 1.12 1.3/0.9 25 29 2.4/3.6 137 ‐1 768 9 A 8 8x6.4
HBV related DCLD/PHT/Multicentric HCC/SHT/CAHD Mrs Malliya 56 1 21‐Jan‐10 2517/10 1500 FALSE TRUE FALSE TRUE FALSE 0 TRUE TRUE FALSE TRUE 1 0 1 TRUE FALSE 10.8 2900 P75L16E09 44000 34.1 15/16 1.0 99 32 1.0 1.2/1.0 27 97 2.5/3.3 332 0 12.8 7 A 9
HCV related DCLD/PHT/Multicentric HCC Mr Maran 55 0 19‐Jul‐10 25269/10 3000 FALSE FALSE TRUE FALSE 2 months FALSE 2 10 180 FALSE FALSE FALSE TRUE 1 1 1 FALSE TRUE 15.6 13500 P72L20E08 166000 46.1 15/14 1.0 160 31.3 0.77 1.0/0.6 25 29 4.4/2.7 206 ‐1 592 6 A 7
Ethanol related DCLD/PHT/HCC Mr Venkateshaw 45 0 09‐Jan‐10 1106/10 3000 FALSE FALSE TRUE FALSE 6 months FALSE 2 15 90 TRUE FALSE FALSE TRUE 0 0 1 FALSE FALSE 10.9 5900 P72L20E08 106000 32 14/15 1.0 268 19 0.44 1.2/0.8 79 57 2.6/4.7 402 ‐1 851 6 A 13 7.3x6.1
Ethanol related DCLD/PHT/HCC
Mr Kalyana 
Sundaram
71 0 30‐Dec‐10 45656/10 3000 TRUE 6 months FALSE FALSE FALSE FALSE 2 10 180 TRUE FALSE TRUE FALSE FALSE FALSE 4.7 3600 P66L19E10 138000 16.9 14/16 1.2 150 26.3 0.85 7.2/5.6 57 25 3.4/2.8 229 0 4 14 B 9 5.8x5.7
HBV related DCLD/PHT/Advanced HCC/PVTright lobe Mrs Nasima 30 1 03‐Jan‐11 271/11 FALSE FALSE TRUE FALSE 1 month FALSE 0 TRUE FALSE TRUE TRUE 1 0 1 TRUE FALSE 7.3 4400 P66L20E10 148000 27.3 15/14 1.0 116 19.2 0.47 1.28/0.8 107 32 3.4/4.2 338 ‐1 300000 6 A 5
13.7x12.
8
HBV related DCLD/PHT/Advanced HCC Mr Ibrahim 47 0 15‐Jul‐11 24817/10 3000 FALSE FALSE TRUE FALSE 1 month FALSE 2 10 180 FALSE FALSE FALSE TRUE 0 0 1 TRUE FALSE 13.3 8500 P71L21E08 394000 44.9 15/14 1.0 112 16.5 0.84 1.0/0.6 111 47 3.6/3.7 218 ‐1 605000 6 A 8 9.4x6.5
HBV related DCLD/PHT/HCC right lobe Mr Pedhutu 29 0 13‐Aug‐09 27327/09 4000 FALSE FALSE TRUE TRUE 2 months FALSE 0 FALSE FALSE FALSE FALSE TRUE FALSE 16 8600 P65L31E04 305000 50.9 15/14 1.0 64 22 0.8 1.2/0.9 20 66 3.4/3,1 2073 0 70.7 6 A 6 20x20
HBV related DCLD/PHT/Bilobar Multicentric HCC Mrs Tamilarasi 50 1 12‐Nov‐10 40242/10 FALSE FALSE TRUE TRUE 4 months FALSE 0 TRUE FALSE FALSE TRUE 1 0 1 TRUE FALSE 12.3 10400 P75L20E10 352000 42.7 15/15 1.0 73 20 0.8 1.4/0.87 135 135 3.3/3.1 1812 0 12.2 6 A 6
HCV related DCLD/PHT/HCC Mr Raman 70 0 16‐Nov‐10 40785/10 FALSE FALSE TRUE FALSE 6 months FALSE 2 15 180 TRUE FALSE FALSE TRUE 1 0 1 FALSE TRUE 11 8200 P69L25E06 392000 34 14/14 1.0 492 30.1 0.9 0.79/0.33 109 33 3.6/3.2 2961 0 0.2 6 A 12
13.5x11.
7
HBV related DCLD/PHT/Advanced HCC Mr Chella Durai 47 0 15‐Apr‐11 12869/11 3000 TRUE 6 months FALSE TRUE TRUE 1 year FALSE 0 TRUE TRUE TRUE TRUE 0 0 1 TRUE FALSE 11.1 6200 P64L24E10 114000 36.5 15/14 1.0 92 19.1 0.7 2.1/1.0 200 183 3.5/3.9 1526 ‐1 986 6 A 3
Ethanol related DCLD/PHT/multicentric HCC/child B Mr Kalliyannan 61 0 03‐Jan‐11 221/11 3000 FALSE FALSE TRUE TRUE 3 years FALSE 0 FALSE FALSE FALSE TRUE 1 0 1 FALSE FALSE 7.5 5300 P71L21E08 85000 27.3 15/15 1.1 95 21 0.6 0.9/0.55 39 27 2.8/3.9 267 0 1.35 6 A 4 5x4
Ethanol related DCLD/PHT/HCC Mr Pardaram 48 0 07‐Nov‐09 38016/09 3000 TRUE 1 month FALSE TRUE TRUE 1 month FALSE 1 10 180 TRUE TRUE TRUE TRUE 1 0 1 FALSE FALSE 11.2 8600 P80L10E10 133000 36.6 15/17 1.3 80 30.2 0.8 6.1/4.0 128 48 1.9/3.2 1128 0 5.28 14 B 4
HBV related DCLD/PHT/HCC/locally advanced Mr Sekhar 44 0 31‐Dec‐09 44779/09 5000 FALSE FALSE TRUE TRUE 3 months FALSE 1 10 180 TRUE FALSE FALSE TRUE 1 0 0 TRUE FALSE 11.9 11900 P74L16E10 430000 40.4 15/16 1.1 125 17.8 0.8 1.5/1.1 54 30 3.5/2.6 928 ‐1 >3000 7 A 10 11.5x7.2
HBV related DCLD/PHT/HCC right lobe Mrs Vellachi 48 1 13‐Jul‐10 24520/10 FALSE FALSE TRUE FALSE 1 month FALSE 0 TRUE FALSE FALSE TRUE 0 0 0 TRUE FALSE 11.3 7000 P65L25E10 309000 37.9 15/14 1.0 139 22.3 0.75 0.9/0.5 100 56 2.8/2.5 214 ‐1 >3000 6 A 10.5x9.5
HCV related DCLD/PHT/HCC right lobe Mr Mannikam 59 0 19‐May‐10 2470/10 11000 FALSE TRUE TRUE TRUE 1 month FALSE 2
occas
ional
FALSE TRUE FALSE FALSE FALSE TRUE 10.8 7200 P60L30E10 457000 32.2 14/26 1.2 183 17.7 0.8 1.0/0.95 26 14 4.1/3.7 185 ‐1 215.71 6 A 4
MASTER CHART 
Ethanol related DCLD/PHT/HE/type 2 DM/HCC Mr Padmanabham 72 0 23‐Apr‐11 2169/11 5000 TRUE 6 months FALSE FALSE FALSE FALSE 2 7 TRUE FALSE FALSE FALSE TRUE FALSE 12.9 8200 P80L09E11 90000 40.9 14/16 1.1 106 33.94 0.76 1.2/0.8 109 31 2.3/2.4 263 ‐1 705 6 A 8.5x8.1
HCV related DCLD/PHT/SBP/HCC/PVT Mr Jhukkanam 48 0 28‐Jan‐11 225/11 2500 TRUE 3 months TRUE TRUE FALSE 2 months FALSE 2 13 180 TRUE TRUE FALSE TRUE 0 0 FALSE TRUE 14 11100 P70L20E10 146000 42.7 14/15 1.0 194 41.2 0.56 3.4/1.9 216 63 3.5/3.4 555 ‐1 11435 6 A
HCV related DCLD/PHT/DM/HCC Mr Ramagle 47 0 11‐Jan‐11 499/11 12000 FALSE FALSE TRUE FALSE 3 months FALSE 0 FALSE FALSE FALSE TRUE 1 0 0 FALSE TRUE 13.9 10100 P65L25E10 281000 43.1 14/22 1.9 95 11.7 0.6 0.8/0.5 36 39 2.9/3.6 431 ‐1 435.6 7 A 4
HBV related DCLD/PHT/PVT/PCC Mr Mohandas 55 0 26‐Jan‐11 246/11 FALSE FALSE FALSE TRUE FALSE 0 FALSE FALSE FALSE TRUE 1 1 TRUE FALSE 10.7 11400 P81L10E09 145000 35.3 15/18 1.3 155 23.82 0.64 1.59/0.99 71 25 2.7/4.7 500 256 6 A 6.9x7.1
HBV related DCLD/PHT/HCC/non alcoholic Mrs Parimala 60 1 12‐Jan‐11 319/11 TRUE 1 month FALSE FALSE TRUE FALSE 0 TRUE FALSE FALSE TRUE 1 0 1 TRUE FALSE 9.2 6900 P67L20E13 255000 29.1 15/17
26/2
8
286 10.33 0.63 1.25/0.66 69 37 2.1/4.7 209 12.3 7 B 6 9.2x9
HBsAg DCLD/PHT/HCC Mr Ragu 60 0 7053/10 TRUE 3 months TRUE TRUE TRUE 2 months FALSE 0 TRUE TRUE FALSE TRUE 1 0 0 FALSE FALSE 10.2 7600 P80L20 120000 33 15/18 1.3 176 30.4 0.9 1.0/0.8 56 48 2/3.2 308 392 14 A 7
HBV related DCLD/PHT/HCC Mr Mahadevan 56 0 149/09 TRUE 3 months FALSE FALSE TRUE FALSE 0 FALSE FALSE FALSE TRUE 0 0 0 TRUE FALSE 9.2 3800 P74L18 85000 32 19 1.3 74 14 0.7 1.4/0.8 63 32 2.1/4.7 190 0.4 6 A 7 8.1x8
HBV related DCLD/PHT/HCC Mr Sundaraj 42 0 3012/10 FALSE FALSE TRUE TRUE 6 months FALSE 2 8 180 TRUE FALSE FALSE TRUE 0 0 0 TRUE FALSE 16.3 7000 P60L30E10 171000 51.3 16 1.2 85 23.3 0.91 1.4/1.0 410 83 3.3/3.8 467 3000 6 B 7
HCV related DCLD/PHT/PVT/multicentric HCC
Mr 
Balasubhramaniam
56 0 09‐Mar‐10 1254/10 TRUE 2 months FALSE TRUE TRUE 1 week FALSE 0 FALSE FALSE FALSE TRUE 1 0 0 FALSE TRUE 13.1 6400 P80L13E07 14000 41.1 18 1.3 95 41.1 0.68 5.2/3.7 17 126 2.5/3.9 697 721.67 6 A 9 4.1x3.4
